Standard Comprehensive Intervention to Treat First-episode Schizophrenia
NCT ID: NCT01057849
Last Updated: 2010-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
600 participants
INTERVENTIONAL
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
NCT06128408
Optimization of Acute Treatment in First Episode Schizophrenia
NCT00157378
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
NCT03289026
Validating and Optimizing Model of Antipsychotics Selection
NCT03237052
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
NCT02532491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risperidone, Intensive
risperidone and intensive psychosocial intervention
risperidone
3-6 mg per day
risperidone, basic
risperidone and basic psychosocial support
risperidone
3-6 mg per day
olanzapine, intensive
olanzapine and intensive psychosocial intervention
olanzapine
5-20 mg per day
olanzapine, basic
olanzapine and basic psychosocial support
olanzapine
5-20 mg per day
aripiprazole, intensive
aripiprazole and intensive psychosocial intervention
Aripiprazole
10-30 mg per day
aripiprazole, basiv
aripiprazole and basic psychosocial support
Aripiprazole
10-30 mg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
risperidone
3-6 mg per day
olanzapine
5-20 mg per day
Aripiprazole
10-30 mg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age between 16-45 years old
* with disease course less than 3 years and during their first episode
* without receiving systematic antipsychotic treatment less than 1 month
Exclusion Criteria
* brain trauma with loss of consciousness more than 1 hour
* current substance misuse (in 3 months) or any substance dependence.
* pregnant women.
* patients with severe suicidal imaginations or behavior.
* mental retardation
* contradict to the study drugs
16 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Science and Technology of the People´s Republic of China
OTHER_GOV
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peking University Institute of Mental Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Yu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peking University Institute of Mental Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anding Hospital
Beijing, Beijing Municipality, China
Beijing Huilongguan Hospital
Beijing, Beijing Municipality, China
Peking University Institute of Mental Health
Haidian District, Beijing Municipality, China
Zhongnan University Xiangya Second Hospital
Changsha, Hunan, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Sichuan University Huaxi Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dai N, Huang B, Gao T, Zheng Y, Shi C, Pu C, Yu X. Initial attitudes toward a drug predict medication adherence in first-episode patients with schizophrenia: a 1-year prospective study in China. BMC Psychiatry. 2023 Dec 5;23(1):907. doi: 10.1186/s12888-023-05419-y.
Cheng Z, Yuan Y, Han X, Yang L, Zeng X, Yang F, Lu Z, Wang C, Deng H, Zhao J, Yu X. Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment? Front Psychiatry. 2020 Jun 19;11:566. doi: 10.3389/fpsyt.2020.00566. eCollection 2020.
Han X, Yuan YB, Yu X, Zhao JP, Wang CY, Lu Z, Yang FD, Dong H, Wu YF, Ungvari GS, Xiang YT, Chiu HF. The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian Arch Psychiatry. 2014 Dec;24(4):169-73.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007BAI17B04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.